NCCN Guidelines for Patients
Hodgkin Lymphoma, Version 1.2015
Overview of cancer treatments Targeted therapy
Targeted therapy is a class of drugs that stops the
action of molecules that help cancer cells grow. It is
less likely to harm normal cells than chemotherapy. At
this time, targeted therapy is not widely used to treat
Hodgkin lymphoma. The drugs approved for certain
Brentuximab vedotin is a targeted therapy that
delivers cell-specific chemotherapy. On the surface
of Hodgkin lymphoma cells are proteins called CD30.
Brentuximab attaches to CD30 and enters cancer
cells. Once inside, it releases the chemotherapy.
By targeting only cells with CD30 receptors, fewer
normal cells are harmed.
Brentuximab vedotin is a treatment option for
classical Hodgkin lymphoma that didn’t respond well
to first-time treatment or that has relapsed. It is also
sometimes given after stem cell transplant. Read
Parts 4.3 and 4.4 for more information. It is slowly
injected into a vein for about 30 minutes. It is often
given every 3 weeks.
The most common side effects include fatigue, low
blood counts, tingling in hands and feet, nausea,
diarrhea, fever, rash, and lung infections. Rare
but severe effects include brain infection, serious
disorder of skin and mucous membranes, and kidney
Inside of cells are protein kinases, called mTor.
Protein kinases are molecules that move chemicals,
called phosphates, from one molecule to another. The
phosphate “turns on” the second molecule.
Everolimus stops mTor from transferring the
phosphate. This action stops the cell from receiving
signals to grow. Everolimus is only an option for
classical Hodgkin lymphoma that was not cured by
first-time treatment. It is made in pill form. It is taken
around the same time every day.
Common side effects include diarrhea, tiredness,
mouth sores, skin rash, cough, and low blood counts.
Serious side effects include other cancers, lung
problems, infections, and kidney failure. Ask your
treatment team for a full list of side effects.
Nodular lymphocyte-predominant Hodgkin lymphoma
is a B-cell lymphoma. On the surface of B-cells are
proteins called CD20. Rituximab attaches to CD20
causing the immune system to attack and kill the
Rituximab is not used alone to treat nodular
lymphocyte-predominant Hodgkin lymphoma. It is
added to chemotherapy. It is a liquid that is injected
into a vein.